Short‐acting β2‐agonist use and asthma exacerbations in Swedish children: A SABINA Junior study

• Published in: Pediatric allergy and immunology 2022-11, Vol.33 (11), p.e13885-n/a
• Main Authors: Melén, Erik, Nwaru, Bright I., Wiklund, Fredrik, Fine Licht, Sofie, Telg, Gunilla, Maslova, Ekaterina, Valk, Ralf J. P., Tran, Trung N., Ekström, Magnus, Janson, Christer
• Format: Article
• Language: English
• Subjects: Adolescent; Adult; Agonists; Allergic; Allergic rhinitis; Asthma; Atopy; Child; Children; Clinical Medicine; Cohort Studies; Comorbidity; Dermatitis; drug therapy; Eczema; epidemiology; exacerbations; Folkhälsovetenskap, global hälsa, socialmedicin och epidemiologi; Food allergies; Health care; Humans; Klinisk medicin; Lungmedicin och allergi; Medical and Health Sciences; Medicin och hälsovetenskap; Original; Patients; pediatric; Pediatrics; Population studies; Public Health, Global Health, Social Medicine and Epidemiology; Respiratory Medicine and Allergy; Rhinitis; SABINA junior study; short-acting β-agonists; short‐acting β2‐agonists; Sweden
• ISSN: 0905-6157; 1399-3038; 1399-3038
• DOI: 10.1111/pai.13885

Background In adults and adolescents with asthma, use of ≥3 short‐acting β2‐agonist (SABA) canisters/year is associated with increased exacerbation risk. Whether this association is present in younger children remains unknown. In this SABA use IN Asthma (SABINA) Junior study, we assessed the association of SABA collection with exacerbation risk in the general Swedish pediatric asthma population. Methods This population‐based cohort study utilized linked data from the Swedish national healthcare registries involving patients with asthma (